Quantitative comparison of estradiol and progesterone receptor contents of primary and metastatic human breast tumors in relation to response to endocrine treatment R. J. B. KingJ. F. StewartJ. L. Hayward Report Pages: 339 - 346
Tumor-associated prostaglandins in patients with primary breast cancer: Relationship to clinical parameters Amy FultonLarry RoiMichael J. Brennan Report Pages: 331 - 337
Tumor cell proliferation and sequential chemotherapy after partial tumor resection in C3H/HeJ mammary tumors Paul G. BraunschweigerLewis M. SchifferSergio Betancourt Report Pages: 323 - 329
Biological meaning of stage and grade in human breast cancer: Review and hypothesis Francis E. Sharkey Review Pages: 299 - 322
Digital dermatoglyphics and breast cancer Murray H. SeltzerChris C. PlatoH. Stephen Fletcher Reports Pages: 261 - 265
Parity and breast cancer: Confirmed evidence of an effect on age at diagnosis Maurizio MacalusoMarcello TamburiniSergio Di Pietro Reports Pages: 257 - 260
Oestrogen and progesterone receptor content and the distribution of histological grade in breast cancer S. ThoresenT. ThorsenF. Hartveit Reports Pages: 251 - 255
Estrogen and progesterone receptors: Correlation of response rates, site and timing of receptor analysis John StewartRoger KingRobert Rubens Reports Pages: 243 - 250
Cellularity and the quantitation of estrogen receptors R. C. MasonR. J. C. SteeleA. P. M. Forrest Reports Pages: 239 - 242
Dolichol-bound oligosaccharides and the transfer of distal monosaccharides in the synthesis of glycoproteins by normal and tumor mammary epithelial cells Armando J. ParodiEdward W. BlankRoberto L. Ceriani Reports Pages: 227 - 237
Prognostic significance of serum IgE levels in primary breast cancer Dennis R. OwnbyHelen E. Ownbythe Breast Cancer Prognostic Study Associates Reports Pages: 221 - 226
The current status of primary radiation therapy in the treatment of early breast cancer Nancy Tarbell LeslieJay R. HarrisSamuel Hellman Review Pages: 213 - 220
Non-contraceptive exogenous estrogens and risk of breast cancer: A review David B. Thomas Review Pages: 203 - 211
Progesterone receptor as a more reliable prognostic parameter than estrogen receptor in patients with advanced breast cancer H. MagdelénatP. PouillartB. Asselain Correspondence Pages: 195 - 195
Variability of steroid receptors in multiple biopsies of breast cancer: Effect of systemic therapy Yeu-Tsu N. (Margaret) Lee Report Pages: 185 - 193
Presurgical radiotherapy decreases the concentrations of estrogen and progesterone receptors in human breast cancer: A 200-patient study N. BressotF. VeithH. Rochefort Report Pages: 177 - 183
Estrogen receptor status as a prognostic indicator for stage I breast cancer patients Joseph P. CroweCharles A. HubayParticipating Investigators Report Pages: 171 - 176
Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer Aman U. BuzdarTerry L. SmithEdmund A. Gehan Report Pages: 163 - 169
The contralateral breast at reconstructive surgery after breast cancer operation — A histopathological study Anita RingbergBjörn PalmerFolke Linell Report Pages: 151 - 161
Luteal phase defect and breast cancer genesis Pierre Mauvais-JarvisRégine Sitruk-WareFrédérique Kuttenn Review Pages: 139 - 150
Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significance V. Craig JordanC. Chem. Review Pages: 123 - 138
Quality control for estrogen receptor quantification by dextran-coated charcoal assay: A single laboratory's experience Shanthi RaamRebecca GelmanJoseph L. Cohen Reports Pages: 111 - 117
The axillary nodes and tumor size in breast cancer F. HartveitM. TangenJ. F. Halvorsen Reports Pages: 105 - 109
Bilateral ovariectomy in premenopausal patients with advanced breast cancer, after the evaluation of estrogen receptors and urinary androgen excretion Saro OrianaGiorgio SecretoFerdinando Preda Reports Pages: 101 - 104
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer Joseph C. AllegraThomas M. WoodcockJames L. Wittliff Reports Pages: 93 - 99
Autologous bone marrow transplantation in metastatic breast cancer Patricia S. Stewart Fourth Annual San Antonio Breast Cancer Symposium Pages: 85 - 92
Adjuvant therapy of breast cancer 1971–1981 Paul P. Carbone Fourth Annual San Antonio Breast Cancer Symposium Pages: 75 - 84
Differentiation of the mammary gland and susceptibility to carcinogenesis Jose RussoLee K. TayIrma H. Russo Review Pages: 5 - 73
Growth regulation of two rat adenocarcinoma cell lines by dexamethasone and progesterone E. JolyF. VignonH. Rochefort Reports Pages: 381 - 389
Nil-8 conditioned medium stimulates growth of human mammary epithelial cells Ian S. FentimanJacky HurstJoyce Taylor-Papadimitriou Reports Pages: 375 - 379
Total prolactin binding sites in human breast cancer biopsies J. P. PeyratD. DewaillyJ. Lefebvre Reports Pages: 369 - 373
Lack of efficacy of xeromammography in preoperatively detecting lobular carcinoma in situ of the breast Don M. MorrisAlonzo P. WalkerDonald C. Coker Reports Pages: 365 - 368
Effect of chemotherapy on survival in metastatic breast cancer Alexander H. G. PatersonOlga SzafranJohn Hanson Reports Pages: 357 - 363
Adjuvant CMF effect on site of first recurrence, and appropriate follow-up intervals, in operable breast cancer with positive axillary nodes P. ValagussaJ. D. Tesoro TessG. Bonadonna Reports Pages: 349 - 356
Surgery in the primary treatment of breast cancer Norman WolmarkBernard Fisher 4th Annual San Antonio Breast Cancer Symposium Pages: 339 - 348
Cytochemistry of sex steroid receptors: A critique K. S. McCarty JrD. S. ReintgenK. S. McCarty Sr. Viewpoints Pages: 315 - 325
Immunohistologic and histochemical methods for detection of steroid binding in breast cancer: A reappraisal Louis P. PertschukEllis H. TobinNorman D. Bloom Viewpoints Pages: 297 - 314
Corpus luteum dysfunction and the epidemiology of breast cancer: A reconsideration Barry M. ShermanRobert B. WallaceStanley G. Korenman Review Pages: 287 - 296
Glycosylated haemoglobin levels in breast cancer patients receiving cytotoxic chemotherapy B. CantwellI. F. ShirleyJ. J. Fennelly Correspondence Pages: 281 - 282